Thursday, 15 October 2026European Markets

DNO Stock Bullish By 15% In The Last 5 Sessions

Loading stream...

(VIANEWS) - Shares of DNO (Oslo Børs Benchmark Index_GI: DNO.OL) jumped by a staggering 15.29% in 5 sessions from kr10.27 to kr11.84 at 05:33 EST on Tuesday, after two consecutive sessions in a row of losses. Oslo Børs Benchmark Index_GI is sliding 0.51% to kr1,195.23, after two successive sessions in a row of losses.

About DNO

DNO ASA engages in the exploration, development, and production of oil and gas assets in the Middle East and the North Sea. Its flagship project is the Tawke field that is located in the Kurdistan region of Iraq. As of December 31, 2021, its proven reserves consisted of 196.1 million barrels of oil equivalent (MMboe); proven and probable reserves included 321.4 MMboe; and proven, probable, and possible reserves consisted of 420.6 MMboe. The company was incorporated in 1971 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, DNO has a trailing twelve months EPS of kr-2.43.

Volume

Today's last reported volume for DNO is 1161515 which is 70.42% below its average volume of 3898840.

More news about DNO (DNO.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com